At the JPM26 conference, Vertex hopes to repeat its success in the treatment of cystic fibrosis in the areas of pain and kidney disease. The company is targeting "five launches in five disease areas over a five-year period." The plan is backed by emerging pain and kidney franchises. Vertex thus expands its portfolio beyond cystic fibrosis. The JPM26 conference takes place in San Francisco from January 12 to 15, 2026. Vertex is one of the companies presenting their strategies there.